Last $2.03 USD
Change Today -0.04 / -1.93%
Volume 81.0K
As of 2:05 PM 06/6/13 All times are local (Market data is delayed by at least 15 minutes).

theragenics corp (TGX) Snapshot

Open
$2.03
Previous Close
$2.07
Day High
$2.05
Day Low
$2.02
52 Week High
05/13/13 - $2.15
52 Week Low
11/19/12 - $1.32
Market Cap
63.0M
Average Volume 10 Days
58.5K
EPS TTM
$0.03
Shares Outstanding
31.1M
EX-Date
--
P/E TM
70.0x
Dividend
--
Dividend Yield
--
TGX:US Historical Stock Quote
TGX:US Advanced Stock Chart

theragenics corp (TGX) Latest News

Study: Underground power lines a problem for Horizon Center [The Knoxville News-Sentinel, Tenn.]
More News

theragenics corp (TGX) Related News

No Related News Found

theragenics corp (TGX) Key Developments

Theragenics Corp. Elects K. Wyatt Engwall as Class III Director

Theragenics Corp. announced that its shareholders elected K. Wyatt Engwall as Class III director to serve a three year term expiring in 2016 were elected.

Theragenics Corp. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2013; Provides Financial Guidance for 2014

Theragenics Corp. announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported total revenue of $19,873,000, operating income of $17,000, loss before income taxes of $92,000 and net loss of $34,000 compared to total revenue of $21,583,000, operating income of $1,576,000, earnings before income taxes of $1,451,000 and net earnings of $934,000 or $0.03 per diluted share a year ago period. Adjusted EBITDA was $2,301,000 against $3,755,000 a year ago. Capital expenditures were $527,000 in the first quarter of 2013. The company expects to incur incremental expenses totaling $3.7 million to $4.1 million through 2014 to complete this restructuring. These incremental costs, expected to be recorded over the restructuring period through December 2014, primarily include severance related expenses and project implementation costs. No significant non-cash charges are expected to be recorded related to this restructuring. Capital expenditures related to restructuring expected to be $2.5 million to $2.7 million through 2014. Upon completion of the restructuring, net cost reductions expected to be $3.3 million to $3.6 million annually.

Theragenics Corp., Q1 2013 Earnings Call, May 09, 2013

Theragenics Corp., Q1 2013 Earnings Call, May 09, 2013


1 TGX 2.19
0.00 (0.00%)

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TGX:US $2.03 USD -0.04

TGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $10.90 USD -0.10
CR Bard Inc $104.33 USD +0.33
Greatbatch Inc $32.10 USD +0.11
Merit Medical Systems Inc $10.17 USD +0.12
Teleflex Inc $76.58 USD +0.07

Industry Analysis

TGX

Industry Average

Valuation TGX Industry Range
Price/Earnings 54.7x
Price/Sales 0.7x
Price/Book 0.8x
Price/Cash Flow 14.1x
TEV/Sales 0.1x
 | 

Post a JobJobs

  • Chief Executive Officer
    Orlando, FL | Consult Soft
    Posted: May 22
  • Corporate Chief Information Officer
    New York, NY |
    Posted: May 17
  • Thornton, CO | U.S. Department of State
    Posted: Jun 04
  • Golden, CO | PETCO
    Posted: Jun 02
Simply Hired

Sponsored Links


otc, otcbb, pinksheet, TGX, ob Theragenics Corp


Theragenics Corp Stock

Theragenics Corporation operates as a medical device company serving the cancer treatment and surgical products markets primarily in the United States and Europe. It operates through two segments, Surgical Products and Brachytherapy Seed. The Surgical Products segment manufactures, markets, and sells disposable devices primarily utilized in surgical procedures. It offers wound closure products, including sutures, needles, and other surgical products; vascular access products comprising introducer sheaths, guidewires, and accessories; and specialty needles consisting of coaxial, biopsy, brachytherapy, guidewire introducer, spinal, and disposable veress, as well as access trocars and other needle-based products. This segment’s products are used in various markets and applications, such as interventional cardiology and radiology, vascular surgery, orthopedics, plastic surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. The Brachytherapy Seed segment manufactures, markets, and sells TheraSeed and I-Seed, which are FDA-cleared devices for treatment of solid localized tumors and localized prostate cancer. The company sells its products primarily to physicians, hospitals and other healthcare providers, original equipment manufacturers, and to a network of distributors. Theragenics Corporation was founded in 1981 and is based in Buford, Georgia.
THERAGENICS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
  Read More...


All quotes are delayed. All information is provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Quote Stock nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing Quote Stock, you agree to our disclaimer.
@2013 www.quote-stocks.com is a part of The Stock Space financial network – (646) 402-6200. ContactUs Disclamier Privacy Policy